Literature DB >> 3945939

Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450.

A G Braun, F A Harding, S L Weinreb.   

Abstract

A metabolite of thalidomide generated by hepatic microsomes inhibited the attachment of tumor cells to concanavalin A-coated polyethylene. Evidence that metabolite formation is mediated by microsomal cytochrome P-450 is presented. Microsomes incubated with thalidomide underwent a type I spectral shift. Metabolite formation was reduced or eliminated by carbon monoxide, SKF-525A, metyrapone, and N-octylamine. Superoxide dismutase treatment had no effect. Metabolite formation required microsomes and NADPH and was dependent on the length of 37 degrees C incubation. The metabolite could be isolated by successive hexane and chloroform extractions. It is likely the inhibitory thalidomide metabolite was generated by a minor cytochrome P-450 species. Whether this thalidomide metabolite is involved in the drug's teratogenic activity remains to be shown.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3945939     DOI: 10.1016/0041-008x(86)90449-7

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  10 in total

Review 1.  Teratogenic effects of thalidomide: molecular mechanisms.

Authors:  Takumi Ito; Hideki Ando; Hiroshi Handa
Journal:  Cell Mol Life Sci       Date:  2011-01-05       Impact factor: 9.261

2.  Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide.

Authors:  Goutam Chowdhury; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2013-12-24       Impact factor: 3.739

3.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 4.  Angiogenesis and prostate cancer: important laboratory and clinical findings.

Authors:  Michael C Cox; Matthew Permenter; William D Figg
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

5.  The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage.

Authors:  Tasaduq H Wani; Anindita Chakrabarty; Norio Shibata; Hiroshi Yamazaki; F Peter Guengerich; Goutam Chowdhury
Journal:  Chem Res Toxicol       Date:  2017-08-02       Impact factor: 3.739

Review 6.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

Review 7.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

8.  Effects of oral thalidomide on rat liver and skin microsomal P450 isozyme activities and on urinary porphyrin excretion: interaction with oral hexachlorobenzene.

Authors:  D Tsambaos; K Bolsen; S Georgiou; A Monastirli; G Goerz
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 9.  Clinical pharmacokinetics of thalidomide.

Authors:  Steve K Teo; Wayne A Colburn; William G Tracewell; Karin A Kook; David I Stirling; Markian S Jaworsky; Michael A Scheffler; Steve D Thomas; Oscar L Laskin
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 5.577

10.  Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others.

Authors:  Etsuko Tokunaga; Hidehiko Akiyama; Vadim A Soloshonok; Yuki Inoue; Hideaki Hara; Norio Shibata
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.